Coya Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: COYA · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $5.50, $23.0 m, $200,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Coya Therapeutics inked a material deal and sold equity, filing an 8-K on Oct 23.
AI Summary
Coya Therapeutics, Inc. announced on October 23, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Coya Therapeutics, including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- October 23, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Coya Therapeutics?
The filing states that Coya Therapeutics, Inc. entered into a material definitive agreement on October 23, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold by Coya Therapeutics?
The filing mentions "Unregistered Sales of Equity Securities" but does not specify the type or amount of equity sold.
What is the primary business of Coya Therapeutics?
Coya Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where is Coya Therapeutics headquartered?
Coya Therapeutics, Inc. is headquartered at 5850 San Felipe St., Suite 500, Houston, Texas 77057.
What is the Commission File Number for Coya Therapeutics?
The Commission File Number for Coya Therapeutics, Inc. is 001-41583.
Filing Stats: 1,266 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2025-10-27 07:36:46
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
- $5.50 — d to the public at an offering price of $5.50 per Share. The Offering is expected to
- $23.0 m — dditional Shares, will be approximately $23.0 million, before deducting underwriting di
- $200,000 — ton, the Company will pay to Wilmington $200,000 and will issue to Wilmington warrants e
Filing Documents
- d52085d8k.htm (8-K) — 34KB
- d52085dex11.htm (EX-1.1) — 181KB
- d52085dex41.htm (EX-4.1) — 92KB
- d52085dex51.htm (EX-5.1) — 8KB
- d52085dex991.htm (EX-99.1) — 11KB
- d52085dex992.htm (EX-99.2) — 11KB
- 0001193125-25-250709.txt ( ) — 545KB
- coya-20251023.xsd (EX-101.SCH) — 3KB
- coya-20251023_lab.xml (EX-101.LAB) — 18KB
- coya-20251023_pre.xml (EX-101.PRE) — 11KB
- d52085d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coya Therapeutics, Inc. Dated: October 27, 2025 /s/ Arun Swaminathan Arun Swaminathan Chief Executive Officer